Abstract:BACKGROUND: Despite the advances in the treatment of chronic hepatitis B virus (HBV) infection, liver transplantation (LT) remains the only hope for many patients with end-stage liver diseases resulting from HBV.OBJECTIVES: The aim of this study was to investigate the rate of HBV recurrence in cases that had undergone LT due to the HBV related liver cirrhosis.PATIENTS AND METHODS: Forty-nine patients who underwent LT due to HBV related cirrhosis since 2001 to 2009 in Shiraz Organ Transplantation Center were enrolled in the present study. They were asked to complete the planned questionnaire and also to sign the informed consent in order to take part in this study. Post-transplant prophylaxis protocol against HBV recurrence was based on a hundred milligrams of lamivudine daily plus intramuscular injections of hepatitis B immune globulin (HBIG) with appropriate dosage to keep anti-HBs antibody titer above 300 IU/L and 100 IU/L in the first six months and afterwards, respectively. Blood samples were obtained and checked for HBsAg, HBeAg, and the titers of Anti -HBsAb as well as Anti- HBeAb with ELISA. A quantitative HBV DNA assay was also done on all samples (GENE-RAD® Real-time PCR).RESULTS: There were 91.8% males and 8.2% females enrolled in the study. The duration of post-transplant prophylaxis ranged from 3 months to 8 years (mean 18.9 ± 19.3 months). HBsAg and HBeAg were positive in 24.5% and 2% of cases, respectively. Real-time PCR for HBV DNA were zero copies/mL in 91.8% of patients, none of which represented a positive value for HBV recurrence (Positive > 10,000 copies/mL). The mean Anti-HBs Ab titer was 231.7 ± 135.9 IU/L; it was above 100 IU/L in 71.4% of patients. Thirty-seven (75.5%) of the patients were taking tacrolimus plus mycophenolate mofetil, 6 (12.2%) were on cyclosporine plus mycophenolate mofetil, and 6 (12.2%) were taking sirolimus plus mycophenolate mofetil. HBsAg was detectable in seven patients taking tacrolimus plus mycophenolate mofetil (18.9%), in four patients taking cyclosporine plus mycophenolate mofetil (66.7%), and in one patient among the six who were taking sirolimus plus mycophenolate mofetil (16.7%). There was no significant statistical correlation between the presence of a positive value for HBsAg and the immunosuppression regimen or Anti HBsAb titer (P ˃ 0.05). Presence of a positive value for HBsAg was not predictive of a positive HBV DNA or its level in blood (P ˃ 0.05).CONCLUSIONS: Post-transplant HBV prophylaxis with lamivudine and intramuscular HBIG with appropriate dosage to keep anti-HBs antibody titer above 300 IU/L in the first six months and above 100 IU/L afterwards is effective for prevention of HBV recurrence after LT.

Novel protocol for prevention from hepatitis B reactivation following living‐donor liver transplantation

Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation

Antiviral prophylaxis against hepatitis B recurrence after liver transplantation: Current concepts

Impact of Human Leukocyte Antigen Matching on Hepatitis B Virus Recurrence after Liver Transplantation.

Prevention of hepatitis B virus reinfection following orthotopic liver transplantation

Prevention of Hepatitis B Virus Reinfection after Orthotopic Liver Transplantation

Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence

Entecavir Combined with Short-term Hepatitis B Immunoglobulin in Preventing Hepatitis B Virus Recurrence in Liver Transplant Recipients

Reactivation Of Hepatitis B After Liver Transplantation: Current Knowledge, Molecular Mechanisms And Implications In Management

HBIG Remains Significant in the Era of New Potent Nucleoside Analogues for Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation

Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts

Efficacy of Newer Nucleos(t)ide Analogs After Hepatitis B Immunoglobulin Discontinuation Against Hepatitis B and D Recurrence in Liver Transplant Recipients

Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation

Hepatitis B Recurrence After Liver Transplantation: A Single Center Experiences and Review the Literature

Frequent incidence of escape mutants after successful hepatitis B vaccine response and stopping of nucleos(t)ide analogues in liver transplant recipients

Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: Analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus

Prophylaxis and Treatment of Hepatitis B Virus Reinfection Following Liver Transplantation.

Prophylactic Strategy Against De Novo Hepatitis B Virus Infection for Pediatric Recipients Who Receive Hepatitis B Core Antibody-Positive Liver Grafts

Incidence of post‐transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection

De novo hepatitis B infection following liver transplantation with core antibody positive grafts: The role of surface antibody status in guiding long‐term prophylaxis

New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence